Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Management tracks: Omeros, EdiGene

Jaime De Leon
August 2, 2018 9:08 PM UTC

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes at Sanofi (Euronext:SAN; NYSE:SNY). Leifke takes over oversight of clinical science and operations, medical affairs and pharmacovigilance from J. Steven Whitaker, who will now lead development of OMS721. The human mAb against mannan binding lectin serine peptidase 2 (MASP2) is in Phase III testing for thrombotic microangiopathies.

Gene editing company EdiGene Inc. (Beijing, China) hired Dong Wei as CEO. He was COO at Treos Bio Ltd. (London, U.K.). Wei is also a veteran of Shire plc (LSE:SHP; NASDAQ:SHPG), Johnson & Johnson (NYSE:JNJ) and BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article